>

Carolyn Bertozzi - Eli Lilly Independent Director

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>ELI</div>
LLY -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Director
Dr. Carolyn R. Bertozzi, Ph.D., is an Independent Director of the Company. She is currently a professor of Chemistry, Chemical and Systems Biology, and Radiology at Stanford University, and an Investigator at the Howard Hughes Medical Institute. From 1996 to 2015, she was a professor of Chemistry and Molecular Biology at the University of California, Berkeley. She holds a bachelors degree in chemistry from Harvard University and a Ph.D. in chemistry from the University of California, Berkeley. Dr. Bertozzi serves on the Public Policy and Compliance Committee and the Science and Technology Committee.
Age: 51  Director Since 2017      
317 276-2000  www.lilly.com

Carolyn Bertozzi Latest Insider Activity

Management Efficiency

The company has Return on Asset of 0.08 % which means that on every $100 spent on asset it made $0.08 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.23 % implying that it generated $0.23 on every 100 dollars invested.
The company has 15.92 B in debt with debt to equity (D/E) ratio of 459.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Eli Lilly And has Current Ratio of 1.15 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Vindi BangaGlaxoSmithKline PLC
2017
Thomas CechMerck Company
2009
Karen VousdenBristol Myers Squibb Company
2018
Carlos RepresasMerck Company
2009
JeanPhilippe CourtoisAstrazeneca PLC
2008
Adriane BrownAllergan Plc
2017
Laurie GlimcherBristol Myers Squibb Company
N/A
Philip HamptonGlaxoSmithKline PLC
2015
Marc DunoyerAstrazeneca PLC
2013
Frans HoutenNovartis AG
2017
Scott GottliebPfizer
2019
Andreas PlantaNovartis AG
2006
Gerald StorchBristol Myers Squibb Company
2012
Jose BaselgaBristol Myers Squibb Company
2018
Mark McClellanJohnson Johnson
2013
Patricia RussoMerck Company
1995
Stephanie BurnsGlaxoSmithKline PLC
2007
Nesli BasgozAllergan Plc
2014
Jennifer DoudnaJohnson Johnson
2018
Carol DavidsonAllergan Plc
2018
John CoganGilead Sciences
2013

Company Summary

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 33625 people.Eli Lilly And Company (LLY) is traded on BATS Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN 46285, United States and employs 33,625 people. Eli Lilly And Company was previously known as ELI LILLY Co and was traded on BATS Exchange under the symbol LLY. Eli Lilly is listed under Pharmaceutical Products category by Fama And French industry classification.

Eli Lilly And Leadership Team

Ellen Marram, Lead Independent DirectorView
Kathi Seifert, Independent DirectorView
Ralph Alvarez, Independent DirectorView
Jamere Jackson, Independent DirectorView
Joshua Smiley, Chief Financial Officer, Senior Vice PresidentView
Fionnuala Walsh, Senior Vice President - Global QualityView
Johna Norton, Senior Vice President - Global QualityView
Juan Luciano, Independent DirectorView
J Fyrwald, Independent DirectorView
Alfonso Zulueta, Senior Vice President and President - Emerging Markets businessView
Jeffrey Simmons, Senior Vice President and President - Elanco Animal HealthView
John Lechleiter, Chairman, CEO and PresView
Anne White, Senior Vice President and Presidentident - Lilly OncologyView
Karen Horn, Independent DirectorView
Leigh Pusey, Senior Vice President - Corporate Affairs and CommunicationsView
Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance OfficerView
Darren Carroll, Senior Vice President - Corporate Business DevelopmentView
Patrik Jonsson, Senior Vice President and President - Lilly Bio-MedicinesView
William Kaelin, Independent DirectorView
Karen Walker, Independent DirectorView
Christi Shaw, Senior Vice President and President - Lilly Bio-MedicinesView
Barton Peterson, Senior Vice President - Corporate Affairs and CommunicationsView
Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy CommitteeView
Enrique Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USAView
Raul Alvarez, Independent DirectorView
Marschall Runge, Independent DirectorView
Michael Harrington, Executive Vice President, General CounselView
David Hoover, Independent DirectorView
Maria Crowe, President - Manufacturing OperationsView
Myles ONeill, Senior Vice President and President - Manufacturing OperationsView
David Ricks, Senior Vice President and Presidentident - Lilly Bio-MedicinesView
Daniel Skovronsky, Senior Vice President - Science and Technology, and President Lilly Research LaboratoriesView
Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research LaboratoriesView
Carolyn Bertozzi, Independent DirectorView
Erik Fyrwald, Independent DirectorView
Aarti Shah, Senior Vice President - Chief Information and Digital OfficerView
Susan Mahony, Senior Vice President and President - Lilly OncologyView
Jackson Tai, Independent DirectorView
Michael Eskew, Independent DirectorView
Katherine Baicker, Independent DirectorView
Stephen Fry, Senior Vice President - Human Resources and DiversityView
Franklyn Prendergast, Independent DirectorView

Stock Performance Indicators

Did you try this?

Run Portfolio Manager Now

   

Portfolio Manager

State of the art Portfolio Manager to monitor and improve performance of your invested capital
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally see Stocks Correlation. Please also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.